INS and Alzheimer disease: Since, impaired insulin metabolism in the AD brain [318], therefore, intranasal insulin delivery in combination with empagliflozin (FDA-approved Type 2 Diabetes drug), is being evaluated clinically (NCT05081219) for mitigating AD and to enhances cognitive and memory abilities [318].